← Back to Clinical Trials
Recruiting NCT02418442

NCT02418442 Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02418442
Status Recruiting
Phase
Sponsor Duke University
Condition Rheumatic Joint Disease
Study Type OBSERVATIONAL
Enrollment 20,000 participants
Start Date 2015-07
Primary Completion 2028-06

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 21 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20,000 participants in total. It began in 2015-07 with a primary completion date of 2028-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.

Eligibility Criteria

Inclusion Criteria: 1. Onset of rheumatic disease prior to age 16 years for JIA and onset prior to age 19 years for all other rheumatic diseases (see appendix A). 2. Subject (and/or parent/legal guardian when required) is able to provide written informed consent and willing to comply with study procedures. 3. Subject and/or parent/legal guardian is willing to be contacted in the future by study staff. Exclusion Criteria: 1\. Greater than 21 years of age at the time of enrollment.

Contact & Investigator

Central Contact

Mara L Becker, MD, MSCE

✉ mara.becker@duke.edu

📞 (919) 419-5032

Principal Investigator

Mara L Becker, MD, MSCE

PRINCIPAL INVESTIGATOR

Duke Clinical Research Insitute

Frequently Asked Questions

Who can join the NCT02418442 clinical trial?

This trial is open to participants of all sexes, up to 21 Years, studying Rheumatic Joint Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02418442 currently recruiting?

Yes, NCT02418442 is actively recruiting participants. Contact the research team at mara.becker@duke.edu for enrollment information.

Where is the NCT02418442 trial being conducted?

This trial is being conducted at Birmingham, United States, Phoenix, United States, Los Angeles, United States, Los Angeles, United States and 11 additional locations.

Who is sponsoring the NCT02418442 clinical trial?

NCT02418442 is sponsored by Duke University. The principal investigator is Mara L Becker, MD, MSCE at Duke Clinical Research Insitute. The trial plans to enroll 20,000 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology